HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.
Salud Publica Mex
; 58(2): 211-9, 2016 Apr.
Article
en En
| MEDLINE
| ID: mdl-27557379
ABSTRACT
OBJECTIVE:
To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. MATERIALS ANDMETHODS:
A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary.CONCLUSION:
The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combining HPV vaccination and hrHPV-based screening to safety extend screening intervals.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Servicios Preventivos de Salud
/
Neoplasias del Cuello Uterino
/
Ensayos Clínicos como Asunto
/
Vacunación
/
Vacunas contra Papillomavirus
/
Detección Precoz del Cáncer
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Evaluation_studies
/
Screening_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
País/Región como asunto:
Mexico
Idioma:
En
Revista:
Salud Publica Mex
Año:
2016
Tipo del documento:
Article